Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis — TRK-820  

Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis Clinical Trial

Official title: A 14 Day, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose, Phase III Clinical Trial to Assess the Efficacy and Safety of TRK-820 in Treating Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether nalfurafine hydrochloride is effective and safe in the treatment for conventional-treatment-resistant pruritus in patients receiving hemodialysis.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis
• Pruritus

• NCT number: NCT01513161
• Study type: Interventional
• Source: SK Chemicals Co.,Ltd.
• Status: Completed
• Phase: Phase 3
• Start date: April 2008
• Completion date: October 2009